Vaccines

For severe was 98 point two %, and for death was a hundred %. The efficacy against hospitalization wasn't calculated, but by the supplementary materials, we see that one person was hospitalized for cove 19 te vaccine group, and 27 were hospitalized in the placibo group, suggesting efficacy around 96 %. While the madernis touts for severe and hospitalized cases are not statistically different from any cove 19, it is possible that the study was under power to detect a small effect on severity. 98 two % is indeed somewhat greater than 93 point two %. And to a lesser extent, so is 96 %. Still, these differences are not much to write home about. These are small gaps. Even if they had been statistically significant, we must keep in mind, of course, that if we had data for covid like illness, this apparent, small, non significant efficacy would probably simply be ana in a negative test, the same way it was in the fiser trial. Alright, the j and j vaccine its less effective at preventing a positive test, and yet it seems to be the one among the vaccions approved in america that has a specific effect on severity. Although they reported very few mild cases, they reported 93 point one % efficacy against hospitalization, 85 point four % against severe critical cove 19, 62 % against moderate cove 19, and 66 point five % against any cove at 19, the difference between hospitalization and moderate cove 19 was statistically significant, and the difference between hospitalization in any cove 19 almost reached significance. This trial then offers a modest suggestion that being vaccinated protects against hospitalization among s who test positive, because the effect on hospitalization seems to be bigger than the effect on testing, on any on testing positive, that is, on being considered a case of cove 19, which meant you got a positive test after you reported becoming ill.

Explaining the "Hospitalization Paradox"

Mastering Nutrition

Remember Everything You Learn from Podcasts